JNJ-75276617
Sponsors
Janssen - Cilag International, Janssen Cilag International, Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting, Janssen Research & Development, LLC
Conditions
Acute LeukemiaAcute Leukemia of Ambiguous LineageAcute LeukemiasAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Luekemia
Phase 1
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
WithdrawnNCT05521087
Start: 2025-12-26End: 2030-01-29Updated: 2025-06-22
A Phase 1/2, First-in-Human Study of theMenin-KMT2A (MLL1)Inhibitor Bleximenib in Participants with Acute Leukemia
RecruitingCTIS2023-506581-31-00
Start: 2021-06-15Target: 86Updated: 2026-01-20
A Phase 1b Study of Bleximenib in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations
Active, not recruitingCTIS2023-506582-58-00
Start: 2022-07-21Target: 86Updated: 2025-10-03
Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy
RecruitingCTIS2024-520154-38-00
Start: 2025-07-29Target: 246Updated: 2025-10-17
HOVON 181 AML: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a double-blind phase 3 study
RecruitingCTIS2025-522767-15-00
Start: 2026-01-27Target: 271Updated: 2026-01-20